CluenexCaris Life Sciences CAI
Caris Life Sciences scores good on business quality (6.1 of 10). Here is why, in plain words, and what our sealed record shows.
Why it matters
- What Caris Life Sciences does
Caris Life Sciences provides precision oncology and molecular profiling services, selling advanced diagnostic testing directly to biopharma partners and clinicians to guide personalized cancer treatments.
- What it does best
Caris dominates precision oncology profiling with top decile revenue growth of 97% that leaves peers like IONS far behind in commercial traction.
- The main risk
A massive post-IPO pullback after doubling in two months shows vulnerability to sentiment shifts that could stall future equity-funded expansion.
Quality, check by check
Scored against its own industry, from company filings.
Operating margins sit at 15.5% with a 10.6% net margin, expanding rapidly as higher revenue scales fixed laboratory costs.
Proprietary molecular datasets lock in biopharma clients who rely on its platform, ranking it in the top quartile for operating margins.
Revenue surged 97% to $990M, dramatically accelerating past historical annual figures as adoption of its molecular profiling widens.
Net cash of $420M and $124M in free cash flow back a solid balance sheet, keeping debt manageable as operations scale.
Insiders
Executives and directors, from SEC Form 4 filings we read ourselves. Open market trades only; grants, option exercises and pre-planned sales left out.
1 insider bought $990K on the open market. 3 sold $27.2M outside pre-planned sales.
Our sealed record on CAI
Verdicts appear here 30 days after we publish them; members see today's. Each one is in the nightly ledger, fingerprinted the night it was made.
The first sealed verdicts appear here on Oct 11, 2026.
Questions
Caris Life Sciences scores good on the Cluenex quality check (6.1 of 10), measured against its own industry. Profitability is fair, moat weak, growth fast and financial health fair.
In the last 90 days of SEC Form 4 filings: 1 insider bought $990K on the open market. 3 sold $27.2M outside pre-planned sales.
Nov 3, 2026.
See CAI today
- Today's verdict on CAI, and why
- Fair value with cautious, base and optimistic cases
- The exact price that would change the verdict
- Which stocks each signal names, the night it fires
Cite this page: Cluenex, “Caris Life Sciences (CAI)”, https://cluenex.com/stocks/cai/, data as of Oct 10, 2026.